Project Roche Pasadena BP39529

Basic data

Title:
Roche Pasadena BP39529
Duration:
01/04/2018 to 31/07/2020
Abstract / short description:
A randomized, double-blind, placebo-controlled, 52-Week Phase II Study to evaluate the efficacy of intravenous RO7046015 (PRX002) in Participants with early Parkinson's Disease with a 52-Week blinded Extension Pasadena

Involved staff

Managers

University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychology
Faculty of Science
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Neurology with Focus on Neurodegenerative Disorders
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Funders

Basel, Switzerland
Help

will be deleted permanently. This cannot be undone.